Therapeutic Potential of Butyrate for Treatment of Type 2 Diabetes.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanistic and clinical literature without systematic review methodology
PubMed 34737725 · doi:10.3389/fendo.2021.761834
What was done
The authors synthesized literature examining the role of gut microbiota and butyrate in type 2 diabetes (T2D) and prediabetes. The review evaluated mechanisms of action (colonocyte fuel, histone deacetylase inhibition, G-protein coupled receptor signaling) and examined human strategies to increase intestinal butyrate, including supplementation with butyrate-producing bacteria, dietary fiber, and fecal microbiota transplantation.
What was found
The abstract reports that a reduction in butyrate-producing bacteria is consistently observed across human cohorts with prediabetes and T2D. Interventions to raise intestinal butyrate levels have shown short-term benefits in humans; however, no specific quantitative effect sizes are provided, and no long-term improvements in glycemic control have been reported to date.
Why it matters
Targeting intestinal butyrate via prebiotics, probiotics, or microbiome transplants is a widely discussed therapeutic avenue for metabolic disease, but this review clarifies that durable glycemic control has yet to be demonstrated clinically.
Limits
This is a narrative review with no systematic search criteria or meta-analytic data presented in the abstract. The abstract provides no quantitative findings, effect sizes, sample sizes, or intervention durations, and human trials conducted so far lack evidence of long-term efficacy.
Cited by
- supports Butyrate is the primary metabolic fuel source for colonocytes.